Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28

Benzinga · 1d ago
Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.